Specialized Proresolving Lipid Mediators: A Potential Therapeutic Target for Atherosclerosis
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15640%2F22%3A73612707" target="_blank" >RIV/61989592:15640/22:73612707 - isvavai.cz</a>
Alternative codes found
RIV/61989592:15110/22:73612707
Result on the web
<a href="https://www.mdpi.com/1422-0067/23/6/3133" target="_blank" >https://www.mdpi.com/1422-0067/23/6/3133</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3390/ijms23063133" target="_blank" >10.3390/ijms23063133</a>
Alternative languages
Result language
angličtina
Original language name
Specialized Proresolving Lipid Mediators: A Potential Therapeutic Target for Atherosclerosis
Original language description
Cardiovascular disease (CVD) is a global public health issue due to its high morbidity, mortality, and economic impact. The implementation of innovative therapeutic alternatives for CVD is urgently required. Specialized proresolving lipid mediators (SPMs) are bioactive compounds derived from ω-3 and ω-6 fatty acids, integrated into four families: Lipoxins, Resolvins, Protectins, and Maresins. SPMs have generated interest in recent years due to their ability to promote the resolution of inflammation associated with the pathogeneses of numerous illnesses, particularly CVD. Several preclinical studies in animal models have evidenced their ability to decrease the progression of atherosclerosis, intimal hyperplasia, and reperfusion injury via diverse mechanisms. Large-scale clinical trials are required to determine the effects of SPMs in humans. This review integrates the currently available knowledge of the therapeutic impact of SPMs in CVD from preclinical and clinical studies, along with the implicated molecular pathways. In vitro results have been promising, and as such, SPMs could soon represent a new therapeutic alternative for CVD.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
10608 - Biochemistry and molecular biology
Result continuities
Project
<a href="/en/project/EF16_019%2F0000868" target="_blank" >EF16_019/0000868: Molecular, cellular and clinical approach to healthy ageing</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
ISSN
1422-0067
e-ISSN
1422-0067
Volume of the periodical
23
Issue of the periodical within the volume
6
Country of publishing house
CH - SWITZERLAND
Number of pages
20
Pages from-to
3133
UT code for WoS article
000775242000001
EID of the result in the Scopus database
2-s2.0-85126101722